Endocrine Abstracts

Introduction: Determining the radiation dose to both the kidneys and malignant lesions from therapeutic administrations of Y-90 DOTATOC is critical for optimal management of neuroendocrine cancer patients. Here, a new dosimetric approach uses PET/CT to quantify the absolute activity of Y-90 immediately after administration to calibrate subsequent tissue clearance monitored with bremsstrahlung SPECT. The dosimetric information is used to personalize subsequent Y-90 DOTATOC dose...